Abstract
Hyperthermia therapy (HT) is the exposure of a region of the body to elevated temperatures to achieve a therapeutic effect. HT anticancer properties and its potential as a cancer treatment have been studied for decades. Techniques used to achieve a localised hyperthermic effect include radiofrequency, ultrasound, microwave, laser and magnetic nanoparticles (MNPs). The use of MNPs for therapeutic hyperthermia generation is known as magnetic hyperthermia therapy (MHT) and was first attempted as a cancer therapy in 1957. However, despite more recent advancements, MHT has still not become part of the standard of care for cancer treatment. Certain challenges, such as accurate thermometry within the tumour mass and precise tumour heating, preclude its widespread application as a treatment modality for cancer. MHT is especially attractive for the treatment of glioblastoma (GBM), the most common and aggressive primary brain cancer in adults, which has no cure. In this review, the application of MHT as a therapeutic modality for GBM will be discussed. Its therapeutic efficacy, technical details, and major experimental and clinical findings will be reviewed and analysed. Finally, current limitations, areas of improvement, and future directions will be discussed in depth.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1316-1328 |
| Number of pages | 13 |
| Journal | International Journal of Hyperthermia |
| Volume | 34 |
| Issue number | 8 |
| DOIs | |
| State | Published - Nov 17 2018 |
Fingerprint
Keywords
- alternating magnetic field
- convection enhanced delivery
- glioblastoma
- Magnetic hyperthermia therapy
- magnetic nanoparticles
ASJC Scopus subject areas
- Physiology
- Physiology (medical)
- Cancer Research
Cite this
Magnetic hyperthermia therapy for the treatment of glioblastoma : a review of the therapy’s history, efficacy and application in humans. / Mahmoudi, Keon; Bouras, Alexandros; Bozec, Dominique; Ivkov, Robert; Hadjipanayis, Constantinos.
In: International Journal of Hyperthermia, Vol. 34, No. 8, 17.11.2018, p. 1316-1328.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Magnetic hyperthermia therapy for the treatment of glioblastoma
T2 - a review of the therapy’s history, efficacy and application in humans
AU - Mahmoudi, Keon
AU - Bouras, Alexandros
AU - Bozec, Dominique
AU - Ivkov, Robert
AU - Hadjipanayis, Constantinos
PY - 2018/11/17
Y1 - 2018/11/17
N2 - Hyperthermia therapy (HT) is the exposure of a region of the body to elevated temperatures to achieve a therapeutic effect. HT anticancer properties and its potential as a cancer treatment have been studied for decades. Techniques used to achieve a localised hyperthermic effect include radiofrequency, ultrasound, microwave, laser and magnetic nanoparticles (MNPs). The use of MNPs for therapeutic hyperthermia generation is known as magnetic hyperthermia therapy (MHT) and was first attempted as a cancer therapy in 1957. However, despite more recent advancements, MHT has still not become part of the standard of care for cancer treatment. Certain challenges, such as accurate thermometry within the tumour mass and precise tumour heating, preclude its widespread application as a treatment modality for cancer. MHT is especially attractive for the treatment of glioblastoma (GBM), the most common and aggressive primary brain cancer in adults, which has no cure. In this review, the application of MHT as a therapeutic modality for GBM will be discussed. Its therapeutic efficacy, technical details, and major experimental and clinical findings will be reviewed and analysed. Finally, current limitations, areas of improvement, and future directions will be discussed in depth.
AB - Hyperthermia therapy (HT) is the exposure of a region of the body to elevated temperatures to achieve a therapeutic effect. HT anticancer properties and its potential as a cancer treatment have been studied for decades. Techniques used to achieve a localised hyperthermic effect include radiofrequency, ultrasound, microwave, laser and magnetic nanoparticles (MNPs). The use of MNPs for therapeutic hyperthermia generation is known as magnetic hyperthermia therapy (MHT) and was first attempted as a cancer therapy in 1957. However, despite more recent advancements, MHT has still not become part of the standard of care for cancer treatment. Certain challenges, such as accurate thermometry within the tumour mass and precise tumour heating, preclude its widespread application as a treatment modality for cancer. MHT is especially attractive for the treatment of glioblastoma (GBM), the most common and aggressive primary brain cancer in adults, which has no cure. In this review, the application of MHT as a therapeutic modality for GBM will be discussed. Its therapeutic efficacy, technical details, and major experimental and clinical findings will be reviewed and analysed. Finally, current limitations, areas of improvement, and future directions will be discussed in depth.
KW - alternating magnetic field
KW - convection enhanced delivery
KW - glioblastoma
KW - Magnetic hyperthermia therapy
KW - magnetic nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85053336799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053336799&partnerID=8YFLogxK
U2 - 10.1080/02656736.2018.1430867
DO - 10.1080/02656736.2018.1430867
M3 - Review article
C2 - 29353516
AN - SCOPUS:85053336799
VL - 34
SP - 1316
EP - 1328
JO - International Journal of Hyperthermia
JF - International Journal of Hyperthermia
SN - 0265-6736
IS - 8
ER -